Literature DB >> 23809043

A single histrelin implant is effective for 2 years for treatment of central precocious puberty.

Katherine A Lewis1, Andrea K Goldyn, Karen W West, Erica A Eugster.   

Abstract

We investigated whether a "yearly" histrelin implant would provide pubertal suppression when left in place for 2 years. Equivalent suppression was observed when comparing 12 and 24 months in 33 children with central precocious puberty. A single implant for 2 years reduces cost and number of implant procedures.
Copyright © 2013 Mosby, Inc. All rights reserved.

Entities:  

Keywords:  CPP; Central precocious puberty; GnRHa; Gonadotropin releasing hormone analog; HPG; Hypothalamic-pituitary-gonadal; LH; Luteinizing hormone; US; Ultrasensitive

Mesh：

Substances：

Year:  2013        PMID： 23809043      PMCID： PMC4063525          DOI： 10.1016/j.jpeds.2013.05.033

Source DB:  PubMed          Journal:  J Pediatr        ISSN： 0022-3476            Impact factor:   4.406


  5 in total

1.  The histrelin implant: a novel treatment for central precocious puberty.

Authors:  Harry J Hirsch; David Gillis; David Strich; Boris Chertin; Amicur Farkas; Tzina Lindenberg; Hadassa Gelber; Irving M Spitz
Journal:  Pediatrics       Date:  2005-12       Impact factor: 7.124

2.  Efficacy and safety of histrelin subdermal implant in children with central precocious puberty: a multicenter trial.

Authors:  Erica A Eugster; William Clarke; Gad B Kletter; Peter A Lee; E Kirk Neely; Edward O Reiter; Paul Saenger; Dorothy Shulman; Lawrence Silverman; Lisa Flood; William Gray; David Tierney
Journal:  J Clin Endocrinol Metab       Date:  2007-02-27       Impact factor: 5.958

3.  Random luteinizing hormone often remains pubertal in children treated with the histrelin implant for central precocious puberty.

Authors:  Katherine A Lewis; Erica A Eugster
Journal:  J Pediatr       Date:  2012-10-03       Impact factor: 4.406

Review 4.  Consensus statement on the use of gonadotropin-releasing hormone analogs in children.

Authors:  Jean-Claude Carel; Erica A Eugster; Alan Rogol; Lucia Ghizzoni; Mark R Palmert; Franco Antoniazzi; Sheri Berenbaum; Jean-Pierre Bourguignon; George P Chrousos; Joël Coste; Sheri Deal; Liat de Vries; Carol Foster; Sabine Heger; Jack Holland; Kirsi Jahnukainen; Anders Juul; Paul Kaplowitz; Najiba Lahlou; Mary M Lee; Peter Lee; Deborah P Merke; E Kirk Neely; Wilma Oostdijk; Moshe Phillip; Robert L Rosenfield; Dorothy Shulman; Dennis Styne; Maïthé Tauber; Jan M Wit
Journal:  Pediatrics       Date:  2009-03-30       Impact factor: 7.124

5.  Results of a second year of therapy with the 12-month histrelin implant for the treatment of central precocious puberty.

Authors:  Samar Rahhal; William L Clarke; Gad B Kletter; Peter A Lee; E Kirk Neely; Edward O Reiter; Paul Saenger; Dorothy Shulman; Lawrence Silverman; Erica A Eugster
Journal:  Int J Pediatr Endocrinol       Date:  2009-02-26
  5 in total
  17 in total

Review 1.  Long acting systemic HIV pre-exposure prophylaxis: an examination of the field.

Authors:  William R Lykins; Ellen Luecke; Daniel Johengen; Ariane van der Straten; Tejal A Desai
Journal:  Drug Deliv Transl Res       Date:  2017-12       Impact factor: 4.617

2.  Characterization of 12 GnRH peptide agonists - a kinetic perspective.

Authors:  Indira Nederpelt; Victoria Georgi; Felix Schiele; Katrin Nowak-Reppel; Amaury E Fernández-Montalván; Adriaan P IJzerman; Laura H Heitman
Journal:  Br J Pharmacol       Date:  2015-11-04       Impact factor: 8.739

Review 3.  Diagnosis and management of precocious sexual maturation: an updated review.

Authors:  Amanda Veiga Cheuiche; Leticia Guimarães da Silveira; Leila Cristina Pedroso de Paula; Iara Regina Siqueira Lucena; Sandra Pinho Silveiro
Journal:  Eur J Pediatr       Date:  2021-03-21       Impact factor: 3.183

Review 4.  Transgender medicine - puberty suppression.

Authors:  Leonidas Panagiotakopoulos
Journal:  Rev Endocr Metab Disord       Date:  2018-09       Impact factor: 6.514

5.  Long-Term Continuous Suppression With Once-Yearly Histrelin Subcutaneous Implants for the Treatment of Central Precocious Puberty: A Final Report of a Phase 3 Multicenter Trial.

Authors:  Lawrence A Silverman; E Kirk Neely; Gad B Kletter; Katherine Lewis; Surya Chitra; Oksana Terleckyj; Erica A Eugster
Journal:  J Clin Endocrinol Metab       Date:  2015-03-24       Impact factor: 5.958

6.  Transgender Youth Experiences with Implantable GnRH Agonists for Puberty Suppression.

Authors:  Brianna J Hobson; Elle Lett; Linda A Hawkins; Robert A Swendiman; Michael L Nance; Nadia L Dowshen
Journal:  Transgend Health       Date:  2022-08-01

7.  Central Precocious Puberty: Update on Diagnosis and Treatment.

Authors:  Melinda Chen; Erica A Eugster
Journal:  Paediatr Drugs       Date:  2015-08       Impact factor: 3.022

Review 8.  Delayed and Precocious Puberty: Genetic Underpinnings and Treatments.

Authors:  Anisha Gohil; Erica A Eugster
Journal:  Endocrinol Metab Clin North Am       Date:  2020-12       Impact factor: 4.741

9.  The association between family impact and health-related quality of life of children with idiopathic central precocious puberty in Chongqing, China.

Authors:  Hong Yang; Shunqing Luo; Xiaohua Liang; Qin Lin; Ting Cheng; Li Zeng; Fang Tang; Di Wu
Journal:  Health Qual Life Outcomes       Date:  2021-06-26       Impact factor: 3.186

10.  Phase 3 Trial of a Small-volume Subcutaneous 6-Month Duration Leuprolide Acetate Treatment for Central Precocious Puberty.

Authors:  Karen O Klein; Analía Freire; Mirta Graciela Gryngarten; Gad B Kletter; Matthew Benson; Bradley S Miller; Tala S Dajani; Erica A Eugster; Nelly Mauras
Journal:  J Clin Endocrinol Metab       Date:  2020-10-01       Impact factor: 5.958
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.